Overexpression of program death-1 in T cells has mild impact on allograft survival

Transplant International

Volumn 21, Issue 1, 2008, Pages 21-29

  Chen, Luqiu ^a   Hussien, Yassir ^a   Hwang, Kwang Woo ^a,b   Wang, Ying ^a   Zhou, Ping ^a   Alegre, Maria Luisa ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Chung Ang University   (South Korea)

Author keywords

Animal models; Costimulators; Immunosuppression experimental; T cells; Tolerance strategies

Indexed keywords

CD2 ANTIGEN; CYCLOSPORIN A; PROGRAM DEATH 1; PROTEIN KINASE LCK; RECEPTOR BLOCKING AGENT; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; GENE CONTROL; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ENGINEERING; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; T LYMPHOCYTE; THYMOCYTE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CYCLOSPORINE; CYTOKINES; DISEASE MODELS, ANIMAL; DNA; FLOW CYTOMETRY; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 36649015604     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00536.x     Document Type: Article

References (30)

1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515.
2. Lin H, Rathmell JC, Gray GS, et al. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998 188 : 199.
3. Tao R, Wang L, Han R, et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 2005 175 : 574.
4. Kitazawa Y, Fujino M, Wang Q, et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007 83 : 774.
5. Hwang KW, Sweatt WB, Brown IE, et al. Cutting Edge: Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells. J Immunol 2002 169 : 633.
6. Fecteau S, Basadonna GP, Freitas A, et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2001 2 : 58.
7. Ariyan C, Salvalaggio P, Fecteau S, et al. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003 171 : 5673.
8. Salvalaggio PR, Camirand G, Ariyan CE, et al. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol 2006 176 : 2292.
9. Masteller EL, Chuang E, Mullen AC, et al. Structural analysis of CTLA-4 function in vivo. J Immunol 2000 164 : 5319.
10. Takahashi S, Kataoka H, Hara S, et al. In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection. Eur J Immunol 2005 35 : 399.
11. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 2006 177 : 1052.
12. Hwang KW, Sweatt WB, Mashayekhi M, et al. Transgenic expression of CTLA-4 controls lymphoproliferation in IL-2-deficient mice. J Immunol 2004 173 : 5415.
13. Dudler J, Li J, Pagnotta M, et al. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 2006 82 : 1733.
14. Subudhi SK, Zhou P, Yerian LM, et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004 113 : 694.
15. Wang S, Bajorath J, Flies DB, et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 2003 197 : 1083.
16. Keir ME, Latchman YE, Freeman GJ, et al. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 2005 175 : 7372.
17. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999 11 : 141.
18. Nishimura H, Minato N, Nakano T, et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998 10 : 1563.
19. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2 K, and non-H-2 antigens in rejection. Transplantation 1973 16 : 343.
20. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005 25 : 9543.
21. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004 574 : 37.
22. Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999 285 : 2122.
23. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001 14 : 523.
24. Lee KY, D'Acquisto F, Hayden MS, et al. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 2005 308 : 114.
25. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006 27 : 195.
26. Ozkaynak E, Wang L, Goodearl A., et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002 169 : 6546.
27. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003 76 : 994.
28. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003 171 : 6929.
29. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005 203 : 98.
30. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 314 : 126.